April 16, 2023 03:45 PM EDTUpdated April 17, 08:24 AM
R&D

Roche's com­bo ther­a­py re­duces risk of liv­er can­cer re­turn­ing but rais­es safe­ty ques­tions: #AACR23

Katherine Lewin

News Reporter

OR­LAN­DO — Roche’s Tecen­triq-Avastin com­bi­na­tion, al­ready ap­proved for one in­di­ca­tion, re­duced the risk of can­cer re­cur­rence among pa­tients af­ter they re­ceived surgery for an ear­ly-stage liv­er …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times